Table 5.

Main effect of ALAD genotype on risk of meningioma by lead exposure status: OR and 95% CI of meningioma, NCI Brain Tumor Study, 1994-1998

ALAD1, cases/controls (n)ALAD2, cases/controls (n)*OR (95% CI)
Ever exposed to lead
    No95/25422/571.1 (0.6-2.0)
    Yes21/16613/284.2 (1.7-10.4)
Highest exposure to lead (μg/m3)
    <1095/25422/571.0 (0.6-2.0)
    10-297/575/115.1 (0.6-43.2)
    30-497/552/61.6 (0.1-21.2)
    ≥507/546/115.5 (0.9-32.6)
Cumulative exposure to lead (μg/m3-y)
    088/23822/521.1 (0.6-2.0)
    1-4919/1034/191.1 (0.2-4.8)
    50-993/354/107.8 (0.7-91.2)
    ≥1006/445/432.4 (1.9-560.9)
Average exposure to lead (μg/m3)
    088/23822/521.1 (0.6-2.0)
    1-416/813/210.7 (0.1-4.8)
    5-99/846/917.3 (2.5-120.1)
    ≥103/174/3
  • NOTE: Models adjusted for age and sex only, unless otherwise specified. Each row represents a separate model.

  • * Includes ALAD1-2 heterozygotes and ALAD2-2 homozygotes.

  • Adjusted for all matching factors: age, sex, race, hospital, and distance of residence from hospital.

  • Number of exposed cases or controls is less than five.